Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Acquires $14,100.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M. Baskies purchased 5,000 shares of Anixa Biosciences stock in a transaction that occurred on Tuesday, January 28th. The shares were bought at an average price of $2.82 per share, with a total value of $14,100.00. Following the completion of the transaction, the director now owns 120,000 shares of the company’s stock, valued at $338,400. This represents a 4.35 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Anixa Biosciences Trading Down 1.4 %

NASDAQ ANIX opened at $2.90 on Friday. The stock has a market capitalization of $93.38 million, a price-to-earnings ratio of -7.44 and a beta of 0.90. The stock has a 50-day moving average of $2.74 and a 200 day moving average of $3.05. Anixa Biosciences, Inc. has a twelve month low of $2.07 and a twelve month high of $4.70.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Equities analysts predict that Anixa Biosciences, Inc. will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences during the third quarter worth about $34,000. Westside Investment Management Inc. lifted its stake in Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares in the last quarter. Tyler Stone Wealth Management boosted its holdings in Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares during the last quarter. Finally, International Assets Investment Management LLC increased its stake in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after buying an additional 23,800 shares in the last quarter. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ANIX has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.